US equities |
SPCX $168.80 ▲+6.19% NVDA $237.47 ▲+1.50% MU $1,064.98 ▼-0.92% TSLA $379.80 ▲+2.49% MSFT $524.89 ▲+1.42% SNDK $1,714.34 ▼-0.33% INTC $116.83 ▼-2.10% META $744.13 ▲+2.21%
FinancialContent

Theralase Technologies Inc (OP:TLTFF)

0.1320 +0.0066 (+5.26%)
Delayed Quote Updated: 1:07 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Theralase Technologies Inc

< Previous 1 2 3 4 Next >
News headline image
Theralase(R) Successfully Completes Non-GLP Toxicity Analysis for Brain Cancer
Via ACCESSWIRE
News headline image
Theralase(R) Grants Stock Options
Via ACCESSWIRE
News headline image
Theralase(R) Closes Private Placement Equity Financing
Via ACCESSWIRE
News headline image
Theralase Release’s 2Q2023 Interim Financial Statements
Via ACCESSWIRE
News headline image
Theralase(R) Closes Non-Brokered Private Placement Equity Financing
Via ACCESSWIRE
News headline image
Theralase(R) Announces Appointment of New Independent Director
Via ACCESSWIRE
News headline image
Theralase(R) Releases Corrected and Restated Press Release for 1Q2023 Interim Financial Statements
Via ACCESSWIRE
News headline image
Theralase(R) Releases 1Q2023 Interim Financial Statements
Via ACCESSWIRE
News headline image
Theralase(R) Appoints Roger DuMoulin-White as President and Chief Executive Officer
Via ACCESSWIRE
News headline image
Theralase Provides Update on Phase II Bladder Cancer Study
Via ACCESSWIRE
News headline image
Theralase Release FY2020 Audited Financial Statements
TORONTO, ON / ACCESSWIRE / April 28, 2021 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and... 
From Theralase Technologies Inc.
Via AccessWire
News headline image
Theralase(R) Releases Quarterly Newsletter
TORONTO, ON / ACCESSWIRE / April 27, 2021 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and... 
From Theralase Technologies Inc.
Via AccessWire
News headline image
Theralase Commences Collaborative Research with National Microbiology Laboratory for Development of Coronavirus Vaccine
TORONTO, ON / ACCESSWIRE / April 9, 2021 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and... 
From Theralase Technologies Inc.
Via AccessWire
< Previous 1 2 3 4 Next >